Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women

NCT00380887

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postmenopause
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
35-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy postmenopausal women aged 35 to 70 years

2. Nonsmoker or smoker of less than 10 cigarettes per day

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. History or presence of clotting disorders


2. History or presence of cancer


3. Presence of HIV, hepatitis B or hepatitis C


4. History of drug or alcohol abuse

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

PostmenopauseStudy Evaluating Premarin and Bazedoxifene Potential Interaction
NCT00745173
  1. Austin, Texas
Female
35 Years+
years
MULTIPLE SITES
PostmenopauseTolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women
NCT00484107
Female
40 Years+
years
MULTIPLE SITES
PostmenopauseStudy Evaluating Bazedoxifene/CE in Postmenopausal Women
NCT00550433
Female
35 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women
Official Title An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women
Brief Summary The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Defined Population
Time Perspective: Other
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition Postmenopause
Intervention Drug: Premarin
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Enrollment
 (submitted: September 26, 2006)
54
Original Enrollment Same as current
Study Completion Date Not Provided
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  1. Healthy postmenopausal women aged 35 to 70 years
  2. Nonsmoker or smoker of less than 10 cigarettes per day

Exclusion Criteria:

  1. History or presence of clotting disorders
  2. History or presence of cancer
  3. Presence of HIV, hepatitis B or hepatitis C
  4. History of drug or alcohol abuse
Sex/Gender
Sexes Eligible for Study:Female
Ages 35 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT00380887
Other Study ID Numbers 0713E1-133, 0713E1-135
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date September 2006